FDA Approves NovoTTF-100L Plus Chemo for Malignant Pleural Mesothelioma

May 23, 2019 – The FDA has approved the NovoTTF-100L System in combination with pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma (MPM), marking the first treatment for this patient population in more than 15 years. The decision is based on findings from the prospective, single-arm STELLAR trial, in which the median overall survival (OS) in … (leggi tutto)